Aristotle University Of Thessaloniki (AUTH)
Association of SUMF1, IREB2, FKBP5 and GLCCΙ1 gene polymorphisms with clinical phenotype, disease progression, and response to glucocorticoid treatment in chronic obstructive pulmonary disease
Abstract
dc:descriptionThis doctoral thesis investigates the genetic underpinnings of Chronic Obstructive Pulmonary Disease (COPD) progression and the differential response to treatment, focusing on polymorphisms within the IREB2, SUMF1, FKBP5, and GLCCI1 genes. COPD, a leading cause of morbidity and mortality globally, is characterized by persistent airflow limitation and an enhanced chronic inflammatory response. The complexity of its pathophysiology and the multifactorial nature of its exacerbations, including environmental exposures and genetic predispositions, underscore the ncessity for personalized treatment approaches. Utilizing data from the HISTORIC study, a double-blind, randomized, placebo-controlled trial, this research examined the associations between specific genetic variants and COPD characteristics, including lung function parameters, and responsiveness to inhaled corticosteroids (ICS), among 165 patients. Our analysis employed multivariable logistic and linear regression models, adjusted for confounders like age, sex, and smoking status, to dissect the role these polymorphisms play in disease progression and treatment efficacy. Results demonstrate notable and novel associations between rs13180, rs2568494 and rs1062980 IREB2 gene polymorphsims and pulmonary function, especially in terms of FEV1change, which serve as a key indicator for assessing the efficacy of ICS treatment. Additionally, the SUMF1 gene variants were linked to altered lung function, hinting at the disruption of the sulfation balance in the lung extracellular matrix as a contributing factor to COPD progression. Furthermore, the study explored the FKBP5 gene rs4713916 polymorphism, previously associated with improved outcomes in COPD rehabilitation, finding similar associations with lung function improvements in our cohort. These genetic markers highlight the potential for precision medicine in COPD, offering insights into patient-specific treatment responses and the disease's heterogeneous nature. Despite the promising findings, the study faced limitations, including a relatively small sample size and a lack of ethnic diversity, which might hinder the generalizability of the results. The exclusion of never-smokers also limits understanding of the genetic factors influencing COPD progression in non-smoking populations. In conclusion, this thesis advances our comprehension of the genetic factors contributing to COPD's complex pathophysiology and the variability in treatment response. It underscores the necessity for larger, more diverse studies to validate these findings and further explore the potential of pharmacogenomics in optimizing COPD management. The goal is to transition from a one-size-fits-all treatment approach to a more tailored strategy, improving patient outcomes while reducing the healthcare burden of COPD. The interplay between genetic predispositions and treatment efficacy opens new avenues for research and patient care, reinforcing the importance of personalized medicine in chronic respiratory diseases.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntenti, Charikleia
- Ντέντη, Χαρίκλεια
Subjects
dc:subject × 12- Φαρμακογενετική
- ΧΑΠ (χρόνια αποφρακτική πνευμονοπάθεια)
- Εισπνεόμενα κορτικοστεροειδή
- Pharmacogenetics
- Chronic obstructive pulmonary disease (COPD)
- Inhaled corticosteroids
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56092